Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tusamitamab ravtansine + pembrolizumab + carboplatin
- Development stage
- Preclinical
- Lead developer
- Sanofi
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This is a **combination drug regimen** that merges three distinct agents: - **Tusamitamab ravtansine** is an antibody-drug conjugate (ADC) targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), delivering the cytotoxic agent ravtansine to CEACAM5-expressing cancer cells. - **Pembrolizumab** is a humanized monoclonal antibody that blocks the programmed cell death protein 1 (PD-1), acting as a checkpoint inhibitor to enhance anti-tumor immune activity. - **Carboplatin** is a platinum-based chemotherapeutic agent causing DNA crosslinking and apoptosis in rapidly dividing cells. This regimen is under investigation in various solid tumors, often in settings where immunotherapy and targeted therapy are combined with cytotoxic chemotherapy to maximize synergistic antitumor effects.
- Brand names
- pembrolizumab (KEYTRUDA)
- Other names
- tusamitamab ravtansinepembrolizumabcarboplatin
02
Targets
TUBB (Tubulin (alpha and beta subunits))CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)PDCD1 (Programmed cell death protein 1 receptor)DNA
Beyond the preview
Go deeper on tusamitamab ravtansine + pembrolizumab + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tusamitamab ravtansine + pembrolizumab + carboplatin.